Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Mar 1;22(1):52-55.
doi: 10.5935/1518-0557.20180011.

ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation

Ludmila Bercaire  1 , Sara Mb Nogueira  1 , Priscila Cm Lima  1 , Vanessa R Alves  1 , Nilka Donadio  1 , Artur Dzik  1 , Mario Cavagna  1
Affiliations
Clinical Trial

ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation

Ludmila Bercaire et al. JBRA Assist Reprod. .

Abstract

Objective: This study aimed to assess a novel protocol designed to improve poor ovarian response through intra-ovarian androgenization. The endpoints were: number of oocytes and mature oocytes retrieved, fertilization, cancellation and pregnancy rates.

Methods: This prospective crossover study enrolled poor responders from previous ovarian stimulation cycles submitted to a novel protocol called ANDRO-IVF. The protocol included pretreatment with transdermal AndroGel(r) (Besins) 25 mg, oral letrozole 2.5 mg and subcutaneous hCG 2500 IU; cycle control was performed with estradiol valerate and micronized progesterone; ovarian stimulation was attained with gonadotropins FSH/LH 450 IU, GnRH antagonist and hCG 5000 IU.

Results: Fourteen poor responders were enrolled. One patient did not meet the inclusion criteria. Thirteen patients previously summited to the standard protocol were offered the ANDRO-IVF Protocol.-Standard Protocol: Mean age: 35.30 years; cancellation rate: 61.53%; mean number of MII oocytes retrieved per patient: 1.8; fertilization rate: 33.33%. Only two patients had embryo transfers, and none got pregnant.-ANDRO-IVF Protocol: Mean age: 35.83 years; cancellation rate: 7.69%; mean number of oocytes retrieved per patient: 5.58, MII oocytes: 3.91. ICSI was performed in 84.61% of the patients and a mean of 1.5 embryos were transferred per patient. Fertilization rate: 62.5%; cumulative pregnancy rate: 16.66%; mean duration of stimulation: 9.77 days.

Conclusion: ANDRO-IVF allows intra-ovarian androgenization by increasing serum and intra-follicular androgen levels and preventing androgen aromatization. This protocol apparently improved clinical outcomes of poor responders in parameters such as number of oocytes retrieved and clinical pregnancy rates. Further randomized controlled trials are needed to confirm these findings.

Keywords: Fertilization in vitro; androgens; fertility agents; oocyte retrieval; ovulation induction; primary ovarian insufficiency.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

References

    1. Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. 2006;21:1884–1893. doi: 10.1093/humrep/del052. - DOI - PubMed
    1. Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis L, Tarlatzis BC. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:127–145. doi: 10.1093/humupd/dmr051. - DOI - PubMed
    1. de los Santos MJ, García-Laez V, Beltrán D, Labarta E, Zuzuarregui JL, Alamá P, Gámiz P, Crespo J, Bosch E, Pellicer A. The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypoandrogenic? Hum Reprod. 2013;28:224–229. doi: 10.1093/humrep/des349. - DOI - PubMed
    1. Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009;24:349–359. doi: 10.1093/humrep/den428. - DOI - PubMed
    1. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, ESHRE working group on Poor Ovarian Response Definition ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–1624. doi: 10.1093/humrep/der092. - DOI - PubMed

Publication types